Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Testosterone Trial Schedules Proposed by Parties in MDL October 22, 2014 Austin Kirk Add Your Comments As attorneys involved in the federal testosterone drug lawsuits prepare to meet with the U.S. District Judge presiding over the litigation later this week, competing proposals have been submitted regarding potential schedules for preparing the first cases for early trial dates. In June 2014, the U.S. Judicial Panel on Multidistrict Litigation (JPML) established centralized all Androgel lawsuits, Testim lawsuits, Axiron lawsuits and other claims involving injuries associated with the use of testosterone gels, creams, patches or injections, regardless of the manufacturer involved in the case. Cases filed in U.S. District Courts nationwide are being transferred to Judge Matthew F. Kennelly in the Northern District of Illinois for coordinated pretrial discovery and a series of bellwether trials to help the parties gauge how juries may respond to certain evidence and testimony that may be introduced throughout the litigation Learn More About Testosterone Lawsuits Testosterone Gel, Patches, Injections or other Treatments May Cause Heart Attacks, Strokes, Wrongful Death. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Testosterone Lawsuits Testosterone Gel, Patches, Injections or other Treatments May Cause Heart Attacks, Strokes, Wrongful Death. Learn More SEE IF YOU QUALIFY FOR COMPENSATION All of the complaints involve similar allegations that side effects of testosterone drugs caused users to suffer a heart attack, stroke, pulmonary embolism, deep vein thrombosis (DVT) or other injury that may have been avoided if the drug makers had provided stronger warnings with the medications. Competing Trial Plans for Testosterone Lawsuits In advance of a status conference scheduled before Judge Kennelly on Friday, attorneys representing plaintiffs and the drug makers have submitted competing proposals regarding the case management schedule that should be adopted by the court to prepare a small group of cases for early trial dates. However, there is very little common ground between the two proposals. A proposed plan submitted by plaintiffs (PDF) calls for the first testosterone trials to begin as early as June 2016. However, the plan submitted by the drug makers (PDF) urges the court to adopt a much longer pretrial schedule, which may delay the start of the first trials until at least late 2017. The plaintiffs are proposing an initial series of six testosterone drug bellwether trials, which would take place between June 15, 2016 and January 31, 2017, allowing for a four-month period between April 2015 and August 2015 for bellwether fact discovery to be completed while discovery into generic liability issues are ongoing. “Despite the fact that this general framework is almost always agreed upon between the parties negotiating case management plans, over the past few weeks Defendants have flatly rejected this typical discovery plan and trial schedule without offering any valid basis for doing so,” wrote attorneys appointed to leadership roles for the plaintiffs in the MDL. Defense attorneys for the drug makers are calling for Judge Kennelly to first address general causation on the link between testosterone and heart problems, indicating that there is not enough scientific evidence to support the plaintiffs claims and arguing that low testosterone levels may be the cause of the injuries. “The efficiencies to be gained by addressing general causation first are obvious,” wrote the Defendants in their proposal. “If Plaintiffs fail to offer reliable expert testimony regarding general causation, these cases will be over without the need for the parties or the Court to expend any further time or resources. Or if the Court finds that there is reliable expert testimony regarding general causation for some injuries but not others, the parties will know what types of plaintiffs to include in the bellwether pool and what types of plaintiffs to exclude.” The Defendants’ proposed schedule does not call for the first trial to begin for another 36 months. Plaintiffs are urging Judge Kennelly to reject this lengthy trial plan in the testosterone litigation, maintaining that it will significantly delay the right to a jury trial, as well as increase the necessary expenses associated with pursuing the cases and generally cause inefficiencies. “[I]t is undeniable that the Defendants’ Unified Case Management Plan wholly prejudices Plaintiffs, who under this plan would be forced to wait over three years before the first trial was to occur (and even then, the defense only allots for two trials), and forces a disjointed inefficient overall discovery schedule,” wrote Plaintiffs in their proposal. “There is simply no reason for this obstruction to the Plaintiffs’ pursuit of justice when the parties are perfectly capable of conducting concurrent discovery, and thereby shortening the time to trial by approximately a year. Testosterone Litigation According to a joint agenda (PDF) submitted on October 17, the status of a unified case management plan is expected to be discussed during a conference scheduled for October 24. In addition, the parties have asked that the court review the status of deposition protocal, direct filing of cases into the MDL, a preservation order, coordination of the federal litigation with state court cases and other pretrial matters. There are currently at least 223 lawsuits pending in the testosterone drug litigation pending before Judge Kennelly in the MDL, according to the latest update (PDF) released by the U.S. JPML on October 15. However, as testosterone injury lawyers continue to review and file cases over the coming months and years, it is ultimately expected that several thousands lawsuits will be brought on behalf of individuals throughout the United States. The cases are centralized before Judge Kennelly for coordinated handling during pretrial proceedings to reduce duplicative discovery into common issues, avoid conflicting rulings from different judges and to serve the convenience of the parties, witnesses and the courts. In complex pharmaceutical litigation, where a large number of lawsuits have been filed involving similar injuries associated with the same or similar medications, it is common for a series of “bellwether” trials to be scheduled in the MDL to help the parties evaluate the relative strengths and weaknesses of their cases. While the outcomes of these early trial dates are not binding on other cases, they may facilitate negotiations to settle testosterone drug injury cases by the manufacturers, avoiding the need for hundreds of individual cases to be set for trial in courts throughout the country. Tags: AndroGel, Axiron, Depo-Testosterone, Heart Attack, Stroke, Testim, Testosterone More Testosterone Lawsuit Stories Link Between Testosterone Drugs and Heart Risks Not Found in New Study June 19, 2023 Study’s Findings Question Link Between Testosterone Drugs and Blood Clots October 26, 2021 New Testosterone Guidelines Warn Against Unnecessary Use, Prefer Shots Over Transdermal Products January 10, 2020 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermPhoneThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (Posted: today) Six women have filed a joint, multiplaintiff BioZorb tissue marker lawsuit, all indicating that they suffered injuries and complications due to the recalled device’s defective design. MORE ABOUT: BIOZORB LAWSUITBioZorb Implant Lawsuit Alleges Tissue Marker Caused Swelling, Fluid Buildup and Chronic Pain (05/14/2025)Four Women File BioZorb Lawsuit Over Breast Tissue Marker Failures and Injuries (05/05/2025)Lawsuit Claims BioZorb Marker Caused Chronic Pain, Multiple Surgeries After Lumpectomy (04/14/2025) 6 Bard PowerPort Lawsuits Selected for Bellwether Trials in Federal MDL (Posted: yesterday) A federal judge has identified the six Bard PowerPort lawsuits that will serve as the first bellwether trials, to test allegations that the port catheters were defectively designed. MORE ABOUT: BARD POWERPORT LAWSUITCourt Indicates Bard PowerPort MDL Bellwether Lawsuits Should Include 3 Infection, 2 Thrombosis and 1 Fracture Case (05/06/2025)Lawyers Proposed 11 Bard Implantable Port Catheter Lawsuits as Bellwether Trial Candidates (04/30/2025)Bard PowerPICC Intravascular Catheter Leaks Linked to Reports of Serious Injuries: FDA (04/21/2025) MDL Judge Orders Paraquat Lawsuit Settlement Update By June 11, 2025 (Posted: 4 days ago) A federal judge has agreed to stay all case-specific discovery deadlines in Paraquat lawsuits, while the parties work to hammer out a settlement agreement to resolve thousands of claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSParaquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (04/16/2025)Appeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025)
New Testosterone Guidelines Warn Against Unnecessary Use, Prefer Shots Over Transdermal Products January 10, 2020
Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (Posted: today) Six women have filed a joint, multiplaintiff BioZorb tissue marker lawsuit, all indicating that they suffered injuries and complications due to the recalled device’s defective design. MORE ABOUT: BIOZORB LAWSUITBioZorb Implant Lawsuit Alleges Tissue Marker Caused Swelling, Fluid Buildup and Chronic Pain (05/14/2025)Four Women File BioZorb Lawsuit Over Breast Tissue Marker Failures and Injuries (05/05/2025)Lawsuit Claims BioZorb Marker Caused Chronic Pain, Multiple Surgeries After Lumpectomy (04/14/2025)
6 Bard PowerPort Lawsuits Selected for Bellwether Trials in Federal MDL (Posted: yesterday) A federal judge has identified the six Bard PowerPort lawsuits that will serve as the first bellwether trials, to test allegations that the port catheters were defectively designed. MORE ABOUT: BARD POWERPORT LAWSUITCourt Indicates Bard PowerPort MDL Bellwether Lawsuits Should Include 3 Infection, 2 Thrombosis and 1 Fracture Case (05/06/2025)Lawyers Proposed 11 Bard Implantable Port Catheter Lawsuits as Bellwether Trial Candidates (04/30/2025)Bard PowerPICC Intravascular Catheter Leaks Linked to Reports of Serious Injuries: FDA (04/21/2025)
MDL Judge Orders Paraquat Lawsuit Settlement Update By June 11, 2025 (Posted: 4 days ago) A federal judge has agreed to stay all case-specific discovery deadlines in Paraquat lawsuits, while the parties work to hammer out a settlement agreement to resolve thousands of claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSParaquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (04/16/2025)Appeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025)